Collegium Pharmaceutical, Inc. reported record net revenue of $144.8 million in Q1 2023, a 73% increase year-over-year, and a GAAP net loss of $(17.4) million, with $(0.51) GAAP loss per share. The company ended the quarter with a cash balance of $269.5 million and reaffirmed its full-year 2023 guidance.
Generated record net revenue of $144.8 million.
Delivered record Belbuca and Xtampza ER net revenue.
Ended Q1 2023 with a cash balance of $269.5 million.
Reaffirmed full year 2023 guidance.
The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Analyze how earnings announcements historically affect stock price performance